Indoco Remedies is currently trading at Rs. 223.00, up by 6.35 points or 2.93% from its previous closing of Rs. 216.65 on the BSE.
The scrip opened at Rs. 226.80 and has touched a high and low of Rs. 226.80 and Rs. 221.50 respectively. So far 129 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 317.00 on 24-Jan-2018 and a 52 week low of Rs. 150.25 on 08-Oct-2018.
Last one week high and low of the scrip stood at Rs. 238.00 and Rs. 203.00 respectively. The current market cap of the company is Rs. 1996.44 crore.
The promoters holding in the company stood at 58.87%, while Institutions and Non-Institutions held 14.97% and 26.16% respectively.
Indoco Remedies has commissioned a new state-of-the-art API manufacturing facility at Patalganga on November 27, 2018. This new cGMP compliant facility will enhance the existing manufacturing capacity from 150 tons to 600 tons p.a.
Major highlights of the facility include, solvent recovery system, automation, energy conservation and Zero Liquid Discharge Effluent Treatment facility. Emphasis on process safety and lant safety has been given by incorporating sophisticated safety devices.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: